Subject Index

A

Absorbable vascular grafts, 197–217
Acellular vascular matrix, 219–235
Aneurysm, 58, 98 See also Failure, vascular grafts
Animal experimental models
baboon,
endothelial cell seeding, 39
graft surface modification, 145–147
dog,
acelluar vascular matrix, 226–235
carotid arteries, 219–235
collagen grafts, 299
endothelial cell seeding, 33–43, 190–195
replamineform small caliber grafts, 60–67
sterility, synthetic grafts, 236–249
pig,
vascular graft evaluation, various materials, 169–178
rabbit,
biodegradable vascular grafts, 200
polyglycolic acid prostheses, 200
Animal origin grafts,
FDA regulation of, 5–6
Antithrombotic drugs See Drugs, antithrombotic
Aortic grafts, 22, 203–214
Applicability of vascular grafts, 278–283, 279 (table)
Arterial surgery See Surgery, vascular
Arteries, 33–43
axillary,
bypass grafts, 27, 29
carotid,
use as vascular grafts, 113, 219–235
coronary,
bypass grafts, 44–49
femoral,
bypass grafts, 25–32,
life table patency, 22 (table)
internal mammary,
use as vascular grafts, 45–46
popliteal,
bypass grafts, 26, 27
Arteriography, 54, 57
Aspirin, 48–49, 192–194, 230
ASTM Committee F-4, Medical Surgical Materials and Devices, 257–262
ASTM Standards
D 276: 77
D 638: 115
D 671: 117–118
D 1059: 77
D 2256: 77
D 3786–80: 116
ASTM Subcommittee F04.04, Cardiovascular Implants and Materials, 262–263

B

Bacteria, 14, 236–249 See also Pyrogens; Sterility
Ball Burst Test
ASTM Standard D 3787–80a: 116
Basement membrane, 219–235
Bench testing
  biological vascular grafts, 111–113
  Dacron® grafts, 108–121
  polytetrafluoroethylene grafts, 108–121
Biocompatibility
  graft testing in various species, 169–249
Biodegradable vascular grafts, 197–217
Bioelectric polyurethane See Polyurethane, bioelectric
Biomaterial surface modification, 137–155
Bioprosthetic vascular grafts, 95–107
Blood compatibility, various materials, 172
Blood flow in vascular grafts, 146–154, 230 (table) See also Patency
Burst testing, 93, 116, 203
  polytetrafluoroethylene, 92 (table)
Bypass grafts
  axillary artery, 27, 29
  coronary artery, 44–49
  distal, 28–29, 52
  extraanatomic, 26–31
  femoral artery, 22 (table), 25–32
  peroneal artery, 52–53
  popliteal artery, 25–32, 52
  tibial artery, 52–53

C

Calcification, vascular grafts, 174 (table)
Calorimeter, 87–89
Carbodiimide stabilizer, 226–235
Cardiac surgery See Surgery, cardiac
Cardiovascular devices
  history of regulation, 253–277
  Cell differentiation, 199–217
  Cell migration, 197–217
  Cell proliferation, 197–217
  endothelial See also Endothelialization
    in absorbable polymeric grafts, 199–217
    biochemistry of, 190
    enzymatic harvest of, 189–196
    use in seeding of grafts, 33–43,
    189–196
    smooth muscle cell interaction, 199
    macrophages, 186, 199–217
    myofibroblasts, 199–215
    platelets, 38–39, 173
    smooth muscle, 199
    various cells, 157 (diagram)
Collagen
  distribution in Dacron grafts, 184 (table)
  effect on healing, 180–188
  quantitative analysis of, 180–188
  small caliber grafts, 293–304
Contact angle measurement, 100
  biosynthetic data plot, 103
Contamination, vascular grafts, 245
"Critical surface tension"
  biosynthetic grafts, 54, 100–102
Cross-linking reagents See Carbodiimide stabilizer; Glutaraldehyde stabilizer
Cyclooxygenase inhibitors, 192–194
D

Dacron vascular grafts
  collagen in, 180–188
  comparison
    in vitro vs animal/human testing
      of various types, 16–24
    to veinous grafts, 13–14
  compound materials, 211–213
  crimped vs noncrimped, 16–24
  endurance of, 16–24, 108–121
  fabrication of, 71–79
  FDA regulation of, 6–7
  fibrinogen adsorption, 143–145, 172–175
  history of development, 11–15, 17–18
  implantation in rabbit aorta, 203–214
  knitted vs woven, 16–24
  microanatomy of, 16–24
  platelet deposition, 172–175
  retrieved human grafts, 180–188
  seeding of, 37–39, 189–196
  spinning of yarn for, 73 (diagram)
  surface modification of, 137–155
  testing of, 80–81, 108–121

Detergents
  acellular matrix preparation, 226

Development of vascular grafts, 11–16

Device performance See Durability;
  Performance, vascular grafts

Diameter, grafts See Small caliber
  grafts

Differential scanning calorimeter, 87–89

Dipyridamole, 48, 192–195

Discharge treatment
  gas, 137
  plasma, 137

Doppler ultrasonic flowmeter, 146, 150

Drugs, antithrombotic, 48, 49 (tables)

aspirin, 48–49, 192–194, 230
  dipyridamole, 48, 192–194
  ibuprofen, 192–194
  U-53,059, 192–194
  U-63557A, 192–194
  Warfarin, 48–49

Durability,
  biological grafts, 111–113
  Dacron grafts, 16–24, 108–121
  polytetrafluoroethylene grafts, 108–121

E

Elasticity
  biosynthetic grafts, 97

Electroosmosis, 292–293

Embolus formation See Thrombus/
  embolus formation

Endothelialization See also Cells, endothelial
  acellular matrix grafts, dog, 232–235
  animal vs human, 14
  in bioelectric polyurethane grafts, 61
  carotid artery grafts, dog, 219–235
  Dacron grafts, dog, 189–196
  man, 18
  drugs and, 189–196
  polyglycolic acid grafts, 200–202
  review, synthetic grafts in dog/
    baboon experimental models, 33–43
  in silicone rubber grafts, 61
  vascular grafts, man, 171, 173
    (table), 174

Endothelium, 33–43

Endotoxins, 242–245

Endurance See Durability

Evaluation
  retrieved vascular grafts, 161–164
Extraanatomic bypass, 26–31
Extremities See Limbs

F
Fabrication, vascular grafts, 71–79
  history of, 18–19
  replamineform, 51, 85–102
  warp knitting, 74–78
  weft knitting, 74–78
Failure, vascular grafts, 14, 98–99, 262–277, 279–280
Fatigue tests
  ASTM Standard D 671: 117–119
FDA See Food and Drug Administration
Fibrinogen adsorption, 143–145, 173
  (table)
Fibrohistiocystic tissue ingrowth, 63–66
Flex tester, 120 (diagram)
Fluoropolymer coatings, 137–155
Food and Drug Administration
  1976 Medical Device Amendment, 284–289
  performance standards development, 284–289
  regulations, 5–9, 284–289
Formaldehyde
  preservation retrieved grafts, 163
  (table)

G
Gas discharge treatment, 137
Glutaraldehyde stabilizer
  in biosynthetic vascular grafts, 99
  in carotid artery grafts, 226–235
  development of, 296–297
  preservation of retrieved grafts, 163
  (table)
  in umbilical cord vein grafts, 50–59
Gore-Tex See Polytetrafluoroethylene, expanded
Growth factors, 199, 209

H
Healing
  human grafts, 11–15, 180–188, 261, 267–268, 270
Hemocompatibility
  graft testing in various species, 169–178
Heparin, 226–228
History, vascular grafts
  development, 11–15, 83–84, 253–277
  legislation, 253–277
Host tissue, 99–100

I
Ibuprofen, 192–195
Infection, 58, 236–249
Inflammatory reaction
  Dacron grafts, 186, 204
  polyglycolic acid grafts, 201
International Center for Artificial Organs and Transplantation (ICAOT), 4

L
Life table patency rates See Patency
Limb salvage, 25–32, 53, 54
Limbs, vascular grafts in
  Dacron grafts, 16–24
  use of glutaraldehyde stabilizer, 50–59, 300
  patency, 22
  polytetrafluoroethylene grafts, 25–32
Lipid imbibition
  umbilical cord vein graft, 54
Long-term morphological changes, 50–59

M
Macrophages, 186, 199–217
Mandril-grown grafts, 103–105
Materials, vascular graft
innovative, 293–305, 293, 294
(tables) See also Dacron; Polydioxanone; Polydimethylsiloxane; Polyesters; Polyethylene, low density; Polylactin 910; Polyglycolic acid; Polytetrafluoroethylene; Polyurethane, bioelectric; Silicone rubber; Teflon®

Medical Device Amendment to the Food, Drug, and Cosmetic Act (1976), 284

Mesh reinforcing of vascular grafts, 51, 85–102

Microanatomy
Dacron grafts, 16–24
Morphological changes
umbilical cord vein graft, 50–59
Mullen Burst Test
ASTM Standard D 3786–80a: 116
Myofibroblasts, 199–215

N
Neointima, 157, 160, 172 See also Endothelialization

O
Occlusion See Patency
Ovine grafts, 105

P
Patency
acellular matrix grafts, 227–229
comparison various graft types, 22 (table)
coronary artery bypass grafts, 47 (table)
Dacron grafts, 16–24, 191–192
effect of antithrombotic drugs, 192 (table)
effect of gas/plasma discharge treatment, 148–154
effect of glutaraldehyde stabilizer, 53, 297–298, 301
polytetrafluoroethylene grafts, 25–32
seeded/non-seeded grafts, 192 (table)
Performance, vascular grafts, 278–305
Plasma discharge treatment, 137–155, 141 (diagram)

Platelets
adhesion, 173 (table)
growth factors, 209
survival in endothelial cell seeded grafts, 38–39

Polydimethylsiloxane (PDMS), 172–176
Polydioxanone, 209, 214
Polyesters See also Dacron vascular grafts
chemical resistance of, 72 (table)
fabrication of, 71–79
history of use in vascular grafts, 11–15
testing of, 77, 80–81
water porosity, 122–136
Polyethylene, low density (LDPE), 172–176
Polyethylene terephthalate See Dacron vascular grafts
Polyglactin 910, 209–214
Polyglycolic acid, 200–211
Polytetrafluoroethylene, expanded (PTFE) vascular grafts
endurance, 108–121
use in limb arterial grafts, 25–32
physical properties, 82–94
dynamic, 92 (table)
static, 92 (table)
seeded grafts, 36, 39
testing of, 84–93, 108–121, 172–175
Polyurethane, bioelectric (BEP), 61–66
Porosity
  effect on polymer strength, 111
  and electrochemical laws, 291–293
gas discharge treatment, 143 (table)
water testing, 85, 122–136, 124
  (diagram)
Preservation, vascular grafts, 156–165
  various methods, 163 (table)
Pressure equivalent electroosmosis, 292–293
Prostacyclin, 38, 193–195, 202
Prostaglandins, 193–195
Prostheses See Arteries; Materials,
  vascular grafts; Veins
Pseudointima, 180–188 See also
  Endothelialization
Pyrogens
  synthetic grafts, 242–249

R
Radio frequency glow discharge treat-
  ment, 137–155
Reconstructive arterial surgery
  See Surgery, vascular
Reinforcing of vascular grafts, 21,
  51, 85–102
Regulation, FDA, 5–9
Replamineform fabrication, 60–67
Research, history of, 253–277
Retrieval, vascular grafts, 158–161,
  265–276
Revascularization, lower limb, 50–
  59, 181–182, 300 See also
  Surgery, vascular

S
Safety and efficacy
  proof for FDA, 284–289
Sea urchin spines, 60–67
SDS-polyacrylamide gel electrophore-
  sis, 183
Seeded grafts, 33–43, 189–196
  patency, 192 (table)
  thrombus formation, 192 (table)
Silicone rubber vascular grafts 61–66,
  294
Sintering, 87–89
Small artery grafts See Small caliber
  grafts
Small caliber grafts (see others)
  acellular vascular matrix, 219–235
  collagen, 293–304
  FDA regulation of, 6–7
  gas/plasma discharge treatment,
  137–155
  history of development, 13–14
  innovative materials, 290–305
  replamineform fabrication, 60–67
  seeded Dacron grafts, 189–196
  surface modification of, 137–155
Sodium dodecyl sulfate (SDS), 226
Species selection, 169–178 See also
  Animal experimental models
Spectroscopy
  electron, 140
  infrared, 99–101
Stabilizers See Carbodiimide stabili-
  zier; Glutaraldehyde stabilizer
Standards development, 5–7, 253–
  290, 304
  FDA procedures, 285–289
  parameters for graft applications,
  281
Sterility
  effect on thrombus formation, 244
  (table)
  synthetic grafts, 236–249
Sterilization techniques, 239–241,
  239 (table)
Strength, vascular grafts, 108–121
  burst tests, 86, 93, 203
  fatigue tests, 117–119
  pressure tests, 116
  MPa, 110
  sintering, 87–89
  suture retention, 86–87, 91–92
tension tests, 85, 92–93, 115
yarn, 110

Surface modification, 137–155
and biological response, 138 (table)

Surgery, vascular, 11–15
   cardiac, 42–49

Suture retention, 86–87, 91–92

Synthetic prostheses See Materials, vascular graft

T

Tanning agents, 296 See also Glutaraldehyde stabilizer; Carbodiimide stabilizer

Teflon, 172–176, 294, 295

Tensile strength tests, 85, 92–93
ASTM Standard D 638: 115

Tests of vascular grafts See also
ASTM Standards
   biocompatibility, 169–178
   biological, 81 (table)
   blood flow, 146–147
   burst, 92–93, 116, 203
   contact angle measurement, 100, 103
   critical surface tensions, 100
   fatigue, 117–119
   porosity, 85, 122–136
   pressure, 116, 213
   pulse cycle, 213–214
   quality assurance, 81 (table)
   tension, 85, 92–93, 115

Thromboxane, 193–195

Thromboxane synthase inhibitors 193–195

Thrombus/embolus formation
   acellular vascular matrix grafts, 229–231
   biosynthetic grafts, 97
   electrochemical laws, 290–305
   endothelial cell seeded grafts, 33–43, 191–195
   fluoropolymer coatings, 147
   in glutaraldehyde stabilized grafts, 55
   and graft surface modification, 147–154
   microemboli, 147, 149
   and preventative drugs, 47–49, 192–194, 230
   in vitro vs in vivo, 148–149, 172–176
   and sterility, 244

   Triton X-100, 226

V

Vascular surgery See Surgery, vascular

Veins, 33–43
   external jugular, 190–195
   saphenous, 13–14, 44–49
   umbilical cord, 50–59, 297

Velouring of graft material, 19, 123
   effect on patency, 22 (table)
   effect on water porosity, 129

W

Warfarin, 48–49

Warp knitting, 19, 74–78
   and life table patency, 22

Water porosity, 122–136

Weft knitting, 18, 74–78
   and life table patency, 22

Y

Yarn
   spinning of, 73 (diagram)
   strength, 110–111